Rimegepant Reduces Migraines: New Hope for Hard-to-Treat Cases

Research Summary

A recent study published in Cephalalgia investigated the effectiveness and tolerability of rimegepant for preventing episodic migraines in adults with poor responses to traditional oral preventive medications. Conducted as a multinational phase 4 trial, the study included a 12-week double-blind treatment phase involving 652 participants. Participants were given either rimegepant or a placebo every other day. Results showed that those taking rimegepant experienced significantly fewer monthly migraine days compared to the placebo group, with an average reduction of 1.6 days. All key secondary outcomes also favored rimegepant, and it was well tolerated with a safety profile similar to placebo.

Study Details

📄 Title: A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications.

👥 Research Team: Pozo-Rosich P et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Nov

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.